Delcath systems, inc. announces inducement grant under nasdaq listing rule 5635(c)(4)

Queensbury, n.y.--(business wire)--delcath systems, inc. (nasdaq: dcth) (the “company” or “delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the company granted equity awards, previously approved by the company's compensation committee, as material inducements to six individuals whose employment commenced in january and february of 2025. the grants resulted in the right to purchase 264,000 shares of the company'.
NDAQ Ratings Summary
NDAQ Quant Ranking